- Location
Curis
"-
Curis Has Obtained The Conditional Approval for Erivedge to Treat Adult Patients
Jul 17, 2013Oncology-focused drug development company Curis has obtained the conditional approval for Erivedge (vismodegib) to treat adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery ...
-
Curis Has Secured US Patent Protecting Intellectual Property Rights
Jun 24, 2013Oncology-focused drug development company Curis has secured US patent protecting intellectual property rights of its phosphoinositide 3-kinase (PI3K) - histone deacetylase (HDAC) inhibitor, CUDC-907. The patent covers the method of ...
Tags: Health&Medicine, Curis, US
-
Curis Announced The Approval of Erivedge for Treatment of Metastatic Basal Cell Carcinoma
May 14, 2013Oncology-focused company Curis has announced the approval of Erivedge (vismodegib) in Australia for the treatment of metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma in adult patients who are not suitable for ...
Tags: Curis, Erivedge Anti-Cancer Drug
-
EMA Has Announced Positive Opinion for Conditional Approval of Curis' Erivedge in EU
May 2, 2013The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has announced positive opinion for conditional approval of Curis' Erivedge in European Union. Erivedge (vismodegib) is used to treat adults with ...
-
Curis Has Reported a Net Loss of $3.38m for The Third Quarter
Nov 29, 2012Curis, a drug development company, has reported a net loss of $3.38m, or $0.04 per share, for the third quarter ended 30 September 2012 compared to a net loss of $4.21m, or $0.05 per share, for the third quarter ended 30 September 2011. ...
Tags: Net Loss, proprietary and licensed programs, clinical trial
